title: Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
abstract: StaphVAX, an unadjuvanted, bivalent vaccine composed of Staphylococcus aureus (S. aureus) capsular polysaccharides (CPS) types 5 and 8 bound to the mutant non-toxic recombinant Pseudomonas aeruginosa exotoxin A (rEPA) conferred approximately 60% protection for 10 months against bacteremia caused by this pathogen in hemodialysis patients. A protective level of 80 microg/ml was estimated based upon geometric mean (GM) antibody levels at the end of the efficacy period. To extend the duration of protection conferred by StaphVAX in hemodialysis patients, recipients of the vaccine were reinjected in a randomized double-blinded, placebo-controlled study. Vaccinees received StaphVAX and a saline placebo injection 14 days apart according to the randomization schedule. The booster dose of StaphVAX was administered an average of 958 days (753-1167 days) after the first injection. There were no serious adverse reactions. Antibody levels at day 14, 28, 92, and 182 post-injection were measured by ELISA. Maximal levels of IgG anti-CPS were observed at the 28-day interval. For type 5, GM antibody levels increased from 73 microg/ml at day 0 to 162 microg/ml (P < 0.001) and for type 8 from 59 microg/ml to 133 microg/ml (P < 0.001). Anti-CPS antibody levels of approximately 80 microg/ml to type 5 and type 8 were achieved in 72.4 and 74.3% of vaccinees, respectively. There was excellent correlation between the level of anti-CPS and opsonic titer (r = 0.93). Moreover, the decline of anti-CPS antibody levels at six months was significantly less rapid than that observed from the first immunization (P < 0.001). We conclude that a booster immunization to maintain protective levels of specific antibodies for an extended period of time is feasible for patients at continuous risk for S. aureus bacteremia.
authors.affiliation: WW Karakawa Microbial Pathogenesis Laboratory, Nabi Biopharmaceuticals, 12280 Wilkins Ave, Rockville, MD 20852, USA. afattom@nabi.com
authors.forename: Ali
authors.initials: A
authors.lastname: Fattom
authors.forename: Steve
authors.initials: S
authors.lastname: Fuller
authors.forename: Myra
authors.initials: M
authors.lastname: Propst
authors.forename: Scott
authors.initials: S
authors.lastname: Winston
authors.forename: Larry
authors.initials: L
authors.lastname: Muenz
authors.forename: David
authors.initials: D
authors.lastname: He
authors.forename: Robert
authors.initials: R
authors.lastname: Naso
authors.forename: Gary
authors.initials: G
authors.lastname: Horwith
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000097:blood; D016667:Bacterial Capsules / Q000276:immunology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects*; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009895:Opsonin Proteins / Q000032:analysis; D010919:Placebos; D011135:Polysaccharides, Bacterial / Q000276:immunology; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000628:therapy; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000009:adverse effects / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D009895:Opsonin Proteins; D010919:Placebos; D011135:Polysaccharides, Bacterial; C423263:StaphVax; D013209:Staphylococcal Vaccines; D018074:Vaccines, Conjugate; C054106:capsular polysaccharide, type 5, Staphylococcus aureus; C064836:capsular polysaccharide, type 8, Staphylococcus aureus